Kornimate/medical-research-clean huggingface dataset:
lifei xiaoji wan treatment's of early-stage nsclc and its impact on the tumor microenvironment

Conditions: Early Stage Lung Adenocarcinoma

Summary: this study evaluated the relationship between the clinical efficacy, histopathological changes and tumor microenvironment of the pharmacopharmacologic lifei xiaoji wan in the treatment of early stage lung adenocarcinoma, and improved high-level clinical evidence and action targets for the prevention and treatment of early stage lung cancer by traditional chinese medicine

lung cancer is a malignant tumor with the highest morbidity and mortality. the microenvironment of tumor plays an important role in its occurrence and development.traditional chinese medicine has great advantages in the prevention and treatment of ground glass pulmonary nodules, but there is a lack of high-level clinical evaluation evidence and precise mechanism of action.lifei xiaoji wan is a prescription based on the theory of "gas accumulation causing cancer". it has good curative effect in treating non-small cell lung cancer. in this study, a single-center randomized controlled study was used to set up a treatment group and a control group to observe and evaluate the clinical efficacy of lifeixiaoji pills on patients with early stage lung adenocarcinoma of ground glass nodules. flow cytometry, pcr array and multiple fluorescence immunofluorescence were used to detect the tumor microenvironment in lung cancer tissues. to investigate the effect of lifeixiaoji pill on tumor microenvironment and its mechanism of action on early lung adenocarcinoma.

Eligibility criteria:
inclusion criteria: * it met the diagnostic criteria of non-small cell lung cancer and was confirmed by pathology, cytology and other relevant examinations. * preoperative thin-slice ct showed pure ground glass pulmonary nodules with a size of 10mm-30mm. intraoperative and postoperative pathology indicated adenocarcinoma, and the tumor stage (tnm) was stage ia. * age: 18-75 years old * expected survival \>5 years * informed consent and sign informed consent exclusion criteria: * patients who have undergone surgery * patients with serious dysfunction of heart, liver, lung, kidney and other important organs * patients with mental illness who were unable to complete the study

Keywords: early stage lung adenocarcinoma tumor microenvironment ground glass nodule
effect of acute obeend exposure on factors regulating appetite

Conditions: Obesity

Summary: n canada, over 60% of adults are classified as overweight and obese resulting in a public health crisis including increasing health care costs and negatively impacting the well-being of many canadians. to overcome these barriers, the obeend device, manufactured by wat medical enterprise, is a new and innovative wellness technology that uses electrical pulses to stimulate acupressure point pc6 to help control appetite. pc6 stimulation could potentially modulate appetite and restore gastric dysfunction, which are important factors that contribute to obesity. if pc6 electrostimulation facilitates the normalization of appetite and restoration of gastric dysfunction in those with obesity, then the device could be a potentially helpful aid to weight loss. to measure the change of appetite hormones and enzymes related to appetite regulation after using the obeend device. the investigators hypothesize that, compared to placebo, acute electrostimulation of pc6 an acupuncture spot on the wrist for a 1 hour period will result in changes in enterogastric hormones in a direction that decreases appetite. this study will provide the first evidence of the acute effects of electrostimulation at pc6 on factors affecting body weight regulation providing insight into the utility of the obeend device for weight control.


Eligibility criteria:
inclusion criteria: * people with obesity (bmi\>30kg/m2) * generally healthy * premenopausal females exclusion criteria: * past (\<1 year) or present use of nicotine products * history of chronic disease or metabolic conditions * females who are pregnant, less than 6 months postpartum, or breastfeeding * diagnosed hepatic disease, renal impairment, uncontrolled hypothyroidism * use of any medications that may affect study outcomes (e.g. hormone replacement therapy)

Keywords: acupuncture wearable wellness device
effect of repetitive transcranial magnetic stimulation in patients with peripheral vestibular dysfunction

Conditions: Peripheral Vestibular Dysfunction

Summary: background: vestibular dysfunctions are common disorders in the adult population that can develop at any life decade. most of the patients with vestibular dysfunction suffer from balance disorders and vertigo that may have a negative impact on daily living activities and social participation. objectives: to investigate the effect of repetitive transcranial magnetic stimulation added to vestibular physical therapy exercises on functional recovery in patients with vestibular dysfunction. hypothesis: there is no effect of repetitive transcranial magnetic stimulation added to vestibular physical therapy exercises on functional recovery in patients with vestibular dysfunction.


Eligibility criteria:
inclusion criteria: * patients diagnosed by an audiologist with a chronic uncompensated unilateral peripheral vestibular weakness * age ranged from 30 to 60 years, and duration of illness ranged from 4 to 32 months exclusion criteria: * benign paroxysmal positional vertigo * bilateral peripheral vestibular weakness * central vestibular disorders * acute vestibular weakness * vertigo of vascular origin (vertebrobasilar insufficiency) or cervical origin

Keywords: vestibular dysfunction, repetitive transcranial magnetic stimulation, vestibular physical therapy exercises, vertigo, activities of daily living.
stereotactic body radiotherapy for hepatocellular carcinoma, and intrahepatic cholangiocarcinoma

Conditions: Carcinoma, Hepatocellular; Intrahepatic Cholangiocarcinoma

Summary: this study is being done to determine if targeted radiation therapy (stereotactic) can be given to treat liver cancer, for patient who are unable to undergo surgery, over a short period of time with a small amount of side effects.


Eligibility criteria:
inclusion criteria: * age ≥ 18 * karnofsky performance status of ≥ 60 * pathologically confirmed ihc or hcc. (pathology not required for hcc if the lesion enhances typically on mri and the patient is evaluated by liver transplant surgery team and thought to have hcc.) * 4 or less separate intrahepatic lesions, with at least one lesion that is able to be followed by easl criteria. * local surgical resection is not possible due to tumor or patient factors * limited metastatic disease is allowed if the volume of metastatic disease does not exceed the volume of primary disease. * prior tace allowed if stopped/completed at least 2 weeks prior to enrollment * prior chemotherapy except sorafenib allowed if stopped/completed at least 2 weeks prior to enrollment * prior sorafenib allowed if stopped/completed at least seven days prior to enrollment. * able to provide signed informed consent exclusion criteria: * childs-pugh score 9 or more * alt or ast ≥ 6 x upper limit of normal * prior history of abdominal irradiation * women who are pregnant or nursing * scheduled to undergo chemotherapy except sorafenib at the time when radiation therapy will be given, or for up to 4 weeks after completion of radiation therapy. * scheduled to undergo sorafenib within seven days of when radiation therapy will be delivered, or for up to 2 weeks after completion of radiation therapy. * undergone prior radiation therapy to the abdomen.
the primary symptoms of gerd(gastroesophageal reflux disease) in chinese outpatients in gastroenterology department

Conditions: Gastroesophageal Reflux

Summary: consecutive patients aged 18-65 years who go to the gastroenterology clinic presented with upper gastrointestinal discomfort would be included. all patients underwent upper endoscopy or an ambulatory 24-h ph(potential of hydrogen) monitoring.pathologic esophageal acid reflux was defined as the percentage total time for which a ph value \ 4.2 % in the distal esophagus. then, patients were treated with esomeprazole 20 mg twice daily for 28 days. the symptom scores were measured by the frequency score multiplied by the severity scores of the predominant symptom before and at the end of the treatment, and the " ppi test " was defined as positive if the overall scores of the predominant dyspeptic symptom in the fourth week decreased by \>50 % compared with those of the baseline. gerd is defined by either 24-hour impedance-ph monitoring or positive ppi(proton pump inhibitor) test or positive result from endoscopy. the percentage of each symptom of gerd in the symptom questionnaire in chinese outpatients in gastroenterology department will be calculated. the symptom of the highest percentage will be the primary symptom.

primary objective：to define the primary symptom of gerd in chinese outpatients in gastroenterology department secondary objective：1. to investigate the symptom distribution of patients who present with symptoms originated from upper gastrointestinal tract and have pathologic esophageal reflux established by 24-hour impedance-ph monitoring, upper endoscopy, or proton pump inhibitor test. 2. to evaluate the life quality of patients with atypical gerd symptoms (symptoms except heartburning and regurgitation) 3. to investigate the diagnostic value of proton pump inhibitor trial to diagnose gerd with atypical reflux symptoms 4. to investigate the predictive value of gerd q to diagnose gerd with atypical reflux symptoms with heartburn or regurgitation

Eligibility criteria:
inclusion criteria: * consecutive patients aged 18-65 years who go to the gastroenterology clinic presented with upper gastrointestinal discomfort, such as heartburn, regurgitation, dysphagia, substernal pain, epigastric pain, epigastric burning, early satiety, postprandial fullness. * whose previous symptoms should last for at least 3 months and be at least 3 days per week in frequency with moderate severity. * able to fill in the questionaires. exclusion criteria: * gastric or duodenal ulcers, upper gi neoplasms on upper endoscopy * severe cardiac or pulmonary diseases, diabetes or rheumatic diseases * history of operations in the upper gi tract * renal failure or abnormal liver function * use of non-steroidal anti-inflammatory drugs (nsaids) * allergy to esomeprazole * pregnancy or lactating mother

Keywords: symptom
a retrospective breast reconstruction study

Conditions: Breast Cancer

Summary: to collect data on patients who have previously undergone breast reconstruction utilizing simpliderm and other hadms.

this study is a retrospective, multi-center, open label study evaluating simpliderm and other human acellular dermal matrices in breast reconstruction. a total of up to 300 patients who underwent direct to implant (one stage) or two-stage unilateral or bilateral breast reconstruction with simpliderm an other hadms at the time of implant or te placement. data will be collected for a minimum of one post-surgical visit after direct implant or exchange. if more visits are available, data from those visits will be collected as well.

Eligibility criteria:
inclusion criteria: * female patient who underwent immediate breast reconstruction post-mastectomy; either direct to implant or with a tissue expander followed by exchange for a saline or gel implant. * hadms such as: integuply, simpliderm, alloderm, flexhd, dermacell, cortiva, or allomax used in the breast reconstruction. exclusion criteria: * female patient who underwent cosmetic/aesthetic breast augmentation procedure or revision. * female patient who underwent delayed breast reconstruction procedure. * female patient who underwent revision of previous breast reconstruction procedure.
is laparoscopic fundoplication better than open fundoplication in children ?

Conditions: Gastroesophageal Reflux

Summary: the aim of the study was to compare short- and longterm outcomes after laparoscopic and open nissen fundoplication in children.


Eligibility criteria:
inclusion criteria: * age 0-15 years * all patients accepted for primary fundoplication at oslo university hospital exclusion criteria: * age over 16 years * parents not speaking norwegian or english well * prior fundoplication * patients with comorbidities considered as unsuited for laparoscopic surgery (diaphragma hernia, several previous abdominal operations etc)

Keywords: gastroesophageal reflux fundoplication randomized controlled trial general surgery child laparoscopy
airway response to repeat allergen challenge and the effect of ibuprofen in mild atopic asthma

Conditions: Atopic Asthma

Summary: the study will assess airway responses in mild atopic asthmatics undergoing repeat allergen challenge testing and will investigate whether ibuprofen changes the response.


Eligibility criteria:
inclusion criteria: * diagnosis of mild asthma, currently well controlled requiring only a bronchodilator (e.g. salbutamol) as needed and infrequently * has allergies that trigger asthma * responds to methacholine challenge at 16mg/ml or less * has fev1 \> 69.5% predicted exclusion criteria: * respiratory illness within 4 weeks * other medical condition assessed by the principal investigator that would put the participant at risk or influence the integrity of the data * pregnant or lactating females * hypersensitivity to ibuprofen
the study of ginkgo leaf dropping pills and huperzine a injection combined with median nerve electrical stimulation in the treatment of cognitive impairment after brain injury

Conditions: Cognitive Impairment After Brain Injury

Summary: this study will conduct a single-center clinical trial to explore the initial therapeutic effect of ginkgo biloba dropping pills, huperzine a injection and median nerve electrical stimulation in patients with cognitive impairment.

specific experimental research methods were randomized, controlled, single-center, exploratory clinical study, through the treatment of ginkgo biloba dropping pills, huperzine a injection and median nerve electrical stimulation in patients with cognitive impairment, to observe the effects of their neuroprotection and cognitive function improvement.

Eligibility criteria:
inclusion criteria: * be over 18 years old * residual cognitive impairment due to brain injury * no previous history of brain-related diseases except this one exclusion criteria: * the patient had severe underlying disease and unstable vital signs * the patient was complicated with consciousness disorder and could not cooperate with cognitive function assessment ③ allergic to drugs or contraindications in drug use ④ there are contraindications of median nerve electrical stimulation
fdg-pet/ct imaging as early predictor of dp

Conditions: Lymphoma

Summary: in this study the investigators would like to describe fdg-pet/ct responses in patients who are receiving cart-19 immunotherapy for follicular lymphoma (fl), diffuse large b-cell lymphoma (dlbcl), and mantle cell lymphoma (mcl) as part of upcc #13413. subjects will undergo two fdg-pet/cts. one performed within 6 weeks of cart-19 infusion and a repeat scan at about 1 month after infusion.

in this study the investigators described fdg-pet/ct responses in patients who were receiving cart-19 immunotherapy for follicular lymphoma (fl), diffuse large b-cell lymphoma (dlbcl), and mantle cell lymphoma (mcl) as part of upcc #13413. subjects underwent two fdg-pet/cts. one performed within 6 weeks of cart-19 infusion and a repeat scan at about 1 month after infusion.

Eligibility criteria:
inclusion criteria: * subjects enrolled on the study upcc 13413 pilot study of redirected autologous t cells engineered to contain anti-cd19 attached to tcr and 4-1bb signaling domains in patients with chemotherapy resistant or refractory cd19+ lymphoma cart-19 autologous t-cell trial with relapsed or refractory dlbcl and fl. as this is a pilot study, we plan to enroll 4 subjects from the two disease types of interest. * subjects ≥ 18 years of age * subjects able to provide informed consent and agree to comply with study procedures exclusion criteria: * subjects who are pregnant or lactating. * subjects will be co-enrolled in this study and upcc 13413 and therefore must comply with the upcc 13413 pilot study of redirected autologous t cells engineered to contain anti-cd19 attached to tcr and 4-1bb signaling domains in patients with chemotherapy resistant or refractory cd19+ lymphoma requirements pertaining to pregnancy, lactation, conception and contraception use throughout their participation in both studies.

Keywords: redirected autologous cart- 19 t-cell immunotherapy
bioavailability study of risperidone orally disintegrating tablets 1 mg of dr.reddy's laboratories limited under fed conditions

Conditions: Healthy

Summary: the purpose of this study was to assess the single-dose relative bioavailability study of 1 mg risperidone orally disintegrating tablets and (risperdal m-tab) under fed conditions.

comparative, randomized, single-dose, 2-way crossover bioavailability study of dr reddy's laboratories ltd. and janssen pharmaceutica products, lp. (risperdal m-tab) 1 mg risperidone orally disintegrating tablets in healthy adult male volunteers under fed conditions

Eligibility criteria:
inclusion criteria: subjects were included in the study only if they met all of the following criteria: * healthy non-smoking (for at least 3 months) adult male volunteers, 18-45 years of age; * weighing at least 60 kg for males and within 15% of their ideal weights (table of "desirable weights of adults", metropolitan life insurance company, 1983); * medically healthy subjects with clinically normal laboratory profiles and ecgs; * voluntarily consent to participate in the study. exclusion criteria: subjects were excluded from the study if there was evidence of any of the following at screening or at any time during the study: * history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, or psychiatric disease. * in addition, history or presence of: * alcoholism or drug abuse within the past year; * hypersensitivity or idiosyncratic reaction to risperidone or benzodiazepines or other antipsychotic drugs; * seizures; * glaucoma or hypermetropia. * positive results on human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag) and hepatitis c virus (hcv) tests. * subjects whose sitting blood pressure is less than 110/60 mm hg at screening or 100/55 mm hg before dosing. * subjects whose pulse is lower than 55 b.p.m. at screening or 50 b.p.m. prior to dosing. subjects whose pr interval is ≥ 190 msec at screening and prior to dosing. * subjects whose ate interval is \> 450 msec at screening and prior to dosing. * subjects with a body temperature ≥38°c before dosing. * subjects who have used any drugs or substances known to be strong inhibitors of cyp enzymes (formerly known as cytochrome p450 enzymes) within 10 days prior to the first dose. * subjects who have used any drugs or substances known to be strong inducers of cyp enzymes (formerly known as cytochrome p450 enzymes) within 28 days prior to the first dose. * subjects who have been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study. * subjects who, through completion of the study, would have donated in excess of: 500 ml of blood in 14 days, or 1500 ml of blood in 180 days, 2500 ml of blood in 1 year. * subjects who have participated in another clinical trial within 28 days prior to the first dose.

Keywords: bioavailability crossover risperidone
management of patients with alpha-1 antitrypsin deficiency associated emphysema

Conditions: Alpha 1-Antitrypsin Deficiency; Emphysema

Summary: the aim of this study is to describe the natural history of patients with alpha-1 antitrypsin associated emphysema and to figure out associated prognostic factors.

all patients who suffer from this disease are followed every 6 months during a 5 years period. fev1 decline is the primary endpoint. quality of life assessed using the saint george's respiratory questionary is recorded too.

Eligibility criteria:
inclusion criteria: * serum alpha one antitrypsin \< 0.8 g/l * emphysema diagnosed by ct scan * adult * obstructive disorder exclusion criteria: * liver or lung transplantation

Keywords: fev1 mortality quality of life
pathogenesis of non-alcoholic steatohepatitis and liver regeneration after bariatric surgery

Conditions: Bariatric Surgery Candidate; Nonalcoholic Steatohepatitis; Obesity

Summary: obesity and obesity related health problems are globally recognized as one of the major threats to public health. bariatric surgery is the most effective and durable therapy option for obesity and the improvement of obesity related co-morbidities. "non alcoholic steatohepatitis" (nash) is an important comorbidity of obesity and improves after surgical intervention. in this study investigators try to enlighten the weight independent mechanism for the effects of bariatric surgery. patients who are assigned to a bariatric procedure will be observed for at least 24 month. a liver and adipose tissue samples are gained during the operation. liver function and morphology are observed before and after operation with limax, fibroscan and ultrasound. systemic inflammation is measured in blood samples before and after surgical intervention. in order to check the microbiome stool samples are collected throughout the entire observation period.

every patient who is scheduled for bariatric surgery in the university hospital aachen will be evaluated for this study. after informed consent baseline measurements are performed preoperative. baseline measurements involve blood and stool samples, limax, fibroscan and ultrasound. during the operation a liver, a subcutaneous and visceral fat sample are taken to analyse liver histology and inflammation as well as fatty tissue signaling. after the operation patients are observed 24 month. further blood samples are taken on the first postoperative day, 2 and 4 weeks, 3, 6, 12, 18 and 24 month after the operation. stool samples are taken 2 and 4 weeks, 3, 6, 12, 18 and 24 month after the intervention. the limax test, a test analysing the liver function, is performed 4 weeks, 6, 12 and 24 month after the operation. the morphologic liver structure is evaluated by fibroscan and ultrasound 4 weeks, 6, 12 and 24 month postoperative.

Eligibility criteria:
inclusion criteria: * \>18 years * scheduled for bariatric surgery * informed consent exclusion criteria: * pregnancy * substance abuse * liver disease other than nash

Keywords: bariatric surgery nonalcoholic steatohepatitis obesity
a dose-escalation study to assess the safety and tolerability of lx214 ophthalmic solution in healthy volunteers, followed by an open-label evaluation of lx214 in patients with keratoconjunctivitis sicca (kcs)

Conditions: Keratoconjunctivitis Sicca

Summary: this is a first-in-man study for the purpose of determining the safety and tolerability of lx214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.


Eligibility criteria:
inclusion criteria: * no systemic disease as determined by a physical examination, clinical laboratory evaluation, and an ecg * schirmer's i test ≥ 10mm/5 minutes with anesthesia * corrected snellen acuity of 20/40 or better in both eyes exclusion criteria: * subjects diagnosed with any ocular disease other than refraction error * subjects with intraocular pressure \>21 mmhg * use of a contact lens within 7 days prior to administration of the first dose * subjects with history of ocular surgery * subjects with a history of laser refractive surgery